ptp1bin2

PTP1B-IN-4 (NUN-17724) is an allosteric PTP1B inhibitor with an IC50 of 8 μM. PTP1B-IN-4 can be used in studies about obesity and diabetes.

PTP1B-IN-2 is an effective protein tyrosine phosphatase 1B (PTP1B) inhibitor(IC50=50 nM).

PTP1B-IN-22 is a protein tyrosine phosphatase 1B (PTP1B) inhibitor that inhibits glucose uptake in skeletal muscle L6 myotubes.

PTP1B-IN-29 (Compound A2B5) is a phosphatase inhibitor that targets protein tyrosine phosphatase 1B (PTP1B), TCPTP, and λPPase, with IC50 values of 1.27 μM, 4.38 μM, and 8.79 μM, respectively. PTP1B-IN-29 is applicable in the research of diabetes and obesity.

PTP1B-IN-27 (Compound 7i) is an inhibitor of protein tyrosine phosphatase 1-B (PTP-1B) with an IC50 of 8.2 µM. Additionally, it inhibits α-glucosidase with an IC50 of 120 µM and exhibits competitive inhibition characteristics (Ki=118 µM).

PTP1B-IN-25 (Compound 19) is an inhibitor of PTP1B with notable antiviral, antibacterial, and antidiabetic activities. It exhibits IC50 values of 0.37 μM for PTP1B, 8.6 μM for HIV, 3.7 μM for α-Glucosidase, and 29 μM for methicillin-resistant Staphylococcus aureus (MRSA).

PTP1B-IN-26 (compound 7a) is a derivative of phenylthiourea-semicarbazone-aryloxy-1,2,3-triazolyl-N-phenylacetamide. It acts as a competitive inhibitor of protein tyrosine phosphatase 1B (PTP-1B) and is applicable in type 2 diabetes research.

PTP1B-IN-20 is a selective PTP1B (protein tyrosine phosphatase 1B) inhibitor with an IC50 of 1.05 μM, demonstrating selectivity over TCPTP (T-cell protein tyrosine phosphatase) with an IC50 of 78.0 μM. It targets a crucial enzyme for inhibiting type 2 diabetes, showing preferential action on PTP1B over TCPTP.

PTP1B-IN-21 is a compound that functions as a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B; IC50=1.56 μM), demonstrating a marked preference over the structurally similar T-cell protein tyrosine phosphatase (TCPTP; IC50>100 μM). This specificity highlights its potential as a critical agent for type 2 diabetes management.